Quick Answer
NovaBridge Biosciences reported R&D Expense of $21.77 million for fiscal year 2024.
NovaBridge Biosciences R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2024 | $21.77M | +1.5% |
| 2023 | $21.45M | -4.9% |
| 2022 | $22.55M | -98.1% |
| 2021 | $1.21B | +23.2% |
| 2020 | $984.69M | +17.2% |
| 2019 | $840.41M | +97.3% |
| 2018 | $426.03M | +59.5% |
| 2017 | $267.07M | +512.6% |
| 2010 | $43.60M | — |
- NovaBridge Biosciences showed an increase of +1.5% in R&D Expense compared to the prior fiscal year.
- Over the 2010–2024 period, NovaBridge Biosciences’s r&d expense has declined by 50.1% (from $43.60 million to $21.77 million).
- The most recent figure is from NovaBridge Biosciences’s fiscal year 2024 report (Form 20-F), filed with the SEC on April 3, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: